ClinicalTrials.gg
RecruitingNCT07447817Updated Oct 27, 2026

Selinexor and Pacritinib in JAK Inhibitor-naïve MF Patients With Cytopenias

A Phase 2 interventional study of Pacritinib and Selinexor in Myelofibrosis, Post-polycythemia Vera Myelofibrosis and Post-essential Thrombocythemia Myelofibrosis, sponsored by John Mascarenhas. Recruiting at 3 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-27.

Sponsored by John Mascarenhas · Phase 2, Interventional, and Treatment

How we know

Updated Oct 27, 2026Now RecruitingSite recruiting status changed+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
26
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 18 studies testing pacritinib in Primary Myelofibrosis — 6 open to participants now, 8 under way, 1 of them phase 3. pacritinib · Primary Myelofibrosis.

Planned enrollment
12th of 18
26 · median 35
Started
2026
with 2 others
Phase 2
8 of 18
4 open now
Registered
17th of 18
by date
Lead sponsor
1 of 18
John Mascarenhas

Among the 18 studies testing pacritinib in Primary Myelofibrosis, this one is the 12th largest by planned enrollment, is one of 3 that started in 2026, is one of 8 in phase 2, and was the 17th registered.

Primary Myelofibrosis

628 studies on the registry are indexed under Primary Myelofibrosis; 126 are open to participants now.

Browse Primary Myelofibrosis studies →

Open to participants now

6 of the 18 studies testing pacritinib in Primary Myelofibrosis are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

About pacritinib

pacritinib: first FDA approval 2022 (VONJO). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 102 Primary Myelofibrosis studies recruiting now, 84 (82%) set no upper age limit and 13 (13%) stop at 75 or younger; 11 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies testing pacritinib in Primary Myelofibrosis, or all of them as a file.
02

Study summary

This is a phase II, multicenter, open-label trial evaluating the safety and efficacy of pacritinib and selinexor in JAK inhibitor naïve patients with anemia and thrombocytopenia.

Read the detailed description

This Phase II, multicenter, open-label will evaluate the safety and efficacy of pacritinib and selinexor in JAK inhibitor naïve patients with anemia and thrombocytopenia. Participants will receive pacritinib monotherapy for 1 cycle (4 weeks) and will be assessed for qualification to proceed to combination therapy at Cycle 2 Day 1. Participants who qualify for combination therapy will receiving pacritinib and selinexor for the remaining cycles. Participants who do not qualify at Cycle 2 Day 1 will have weekly assessments and count checks. If they meet criteria for combination therapy at any point, selinexor will be added onto pacritinib. Participants who do not qualify for combination therapy by Cycle 4 Day 1 will complete 6 cycles of pacritinib monotherapy, complete primary endpoint assessments after 24 weeks, and discontinue study participation. Participants receiving combination therapy must demonstrate clinical benefit at Cycle 7 Day 1 (24 weeks) to continue receiving therapy until loss of response, disease progression, unacceptable toxicity, participant/physician withdrawal, or the study is terminated.

03

Conditions studied

  • Myelofibrosis
  • Post-polycythemia Vera Myelofibrosis
  • Post-essential Thrombocythemia Myelofibrosis

Keywords

  • Myelofibrosis
  • Anemia
  • Thrombocytopenia
  • Pacritinib
  • Selinexor
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults ≥ 18 years of age capable of providing
  • confirmed diagnosis of PMF, post-ET MF, or post-PV MF as per the World Health Organization (WHO) diagnostic criteria - Intermediate-1, Intermediate-2, or High-Risk disease by the Dynamic International Prognostic Scoring System (DIPSS)
  • (ECOG) performance status ≤ 2
  • Baseline splenomegaly ≥ 5cm palpable below the left costal margin and in the midclavicular line OR ≥ 450cc by imaging (i.e. ultrasound, CT, MRI)
  • Baseline anemia, defined by \< 10 g/dL within 28 days prior to Cycle 1 Day 1
  • Baseline thrombocytopenia, defined by count 50-150 x 109/L without platelet transfusions within 28 days prior to Cycle 1 Day 1
  • Adequate organ function as demonstrated by the following within 28 days prior to Cycle 1 Day 1:

    • (SGPT) and/or AST (SGOT) ≤ 3x the (ULN), or ≤ 4 x ULN if, upon judgment of the treating physician, it is believed to be due to MF-related extramedullary hematopoiesis (EMH);
    • Direct ≤ 1.5 x ULN; or ≤ 2x ULN if, upon judgment of the treating physician, it is believed to be due to MF-related extramedullary hematopoiesis (EMH) or documented Gilbert's syndrome;
    • ≥ 30 mL/min;
    • (PT) and activated partial thromboplastin time (aPTT) ≤ 1.5 × ULN (Exceptions to coagulation parameters may be considered for patients who are taking concomitant anticoagulation medications or have a documented anti-phospholipid antibody, after discussion with Study Chair approval)
    • Bone marrow and/or peripheral blood blast count \< 5%; and
    • (ANC) ≥ 1500 mm3 without need for growth factors within 7 days prior to Cycle 1 Day 1.
  • Recovery to ≤ Grade 1 or baseline of any toxicities due to prior systemic treatments, excluding alopecia
  • of at least six months
  • Patients with active virus are eligible if antiviral therapy for hepatitis B has been given for >8 weeks and the viral load is \<100 IU/mL.
  • Patients with history of virus (HCV) are eligible if they have received adequate curative anti-HCV treatment and HCV viral load is below the limit of quantification.
  • Patients with history of are eligible if they have cluster of differentiation (CD)4+ T-cell counts ≥350 cells/μL, negative viral load, and no history of acquired immunodeficiency syndrome (AIDS)-defining opportunistic infections in the last year and should be on established antiretroviral therapy for at least 4 weeks.
  • Women of (WOCBP) and men must agree to use adequate prior to study entry, for the duration of study participation, and for 90 days following completion of therapy. Men must agree to use a condom and not father a child or donate sperm for the duration of the study and for 90 days after the last dose of study therapy
  • Able to adhere to the study visit schedule and all protocol requirements

Exclusion criteria

Exclusion Criteria:

  • Prior treatment with Janus kinase (JAK) inhibitors
  • Prior treatment with selinexor or other Exportin 1 (XPO1) inhibitors
  • Treatment with any MF-directed therapy (including therapies and excluding hydroxyurea) within 2 weeks or 5.5 half-lives, whichever is shorter, of Cycle 1 Day 1
  • Completed hematopoietic cell transplant (HCT)
  • Prior splenectomy, splenic irradiation, or splenic artery embolization within 6 months of Cycle 1 Day 1
  • Impairment of gastrointestinal (GI) function or GI disease that could significantly alter the absorption of pacritinib or selinexor, including any unresolved nausea, vomiting, or diarrhea > National Cancer Institute (NCI CTCAE) v6.0 Grade 1
  • Uncontrolled or currently progressing ocular toxicities
  • Moderate or severe cardiovascular disease meeting one or both of the below criteria:

    • Presence of cardiac disease, including a myocardial infarction within 6 months prior to study entry, unstable angina pectoris, Class III/IV congestive heart failure, or uncontrolled hypertension
    • Documented major (ECG) abnormalities (not responding to medical treatments)
  • Grade 2 or greater bleeding event within the past 6 months
  • corrected by the Fridericia method (QTcF) prolongation > 480 ms or other factors that increase the risk for QT interval prolongation (eg, hypokalemia [defined as serum potassium \< 3.0 mEq/L that is persistent and to correction], or history of long QT interval syndrome)
  • Recipient of organ transplant
  • History of major surgery or any planned surgical procedures within 28 days prior to Cycle 1 Day 1
  • Other within the last three years, other than curatively treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix, organ-confined or treated non- prostate cancer with normal prostate-specific antigen, in situ breast carcinoma after complete surgical resection, or superficial/non-invasive transitional cell bladder carcinoma.
  • Presence of active serious infection
  • Use of any prohibited medications (5.8) within two weeks or five half-lives, whichever is longer, prior to Cycle 1 Day 1
  • Women who are pregnant or lactating
  • Any serious, unstable medical or psychiatric condition that would prevent (as judged by the Investigator) the subject from signing the form (ICF) or any condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk if they were to participate in the study or confounds the ability to interpret data from the study
  • Is or has an immediate family member (e.g., spouse, parent/legal guardian, sibling, or child) who is investigational site or sponsor staff directly involved with this trial, unless prospective IRB approval (by chair or designee) is given allowing exception to this criterion for a specific subject
Terms in these criteria, in plain language(25)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
26 participants (estimated)

Study arms

  • Experimental
    Pacritinib/Selinexor

    Study participants will receive pacritinib monotherapy (200mg BID orally) for the first cycle (28 days). If they qualify to add on selinexor at any point from Cycle 2 Day 1 to Cycle 4 Day 1, participants will have selinexor (60mg QW orally) added onto their pacritinib regimen.

    Drug: Pacritinib · Drug: Selinexor

Interventions

  • Pacritinib 200mg twice a day (BID) by mouth (PO)

    Also known as: VONJO

  • Selinexor 60mg once weekly (QW) by mouth (PO)

    Also known as: KPT-330; XPOVIO

06

What researchers measure

Primary outcomes

  1. Change in spleen volume

    Evaluate clinical efficacy of pacritinib and selinexor in myelofibrosis patients who are JAK inhibitor-naïve and have anemia and thrombocytopenia by assessing spleen volume reduction (SVR) of 35% or greater compared to baseline as measured by imaging (MRI/CT)

    Time frame: Baseline and 24 weeks

Secondary outcomes

  1. Spleen response rate

    Spleen response rate (by palpation) after 6 and 12 cycles; spleen response is defined as baseline splenomegaly palpable at 5-10cm that becomes not palpable, or baseline splenomegaly of \>10cm that decreases by ≥ 50%, as measured by palpation

    Time frame: At 24 weeks and 48 weeks

  2. Change in the Myelofibrosis-Symptom Assessment Form Total Symptom Score (MF-SAF TSS)

    Evaluate change in patient reported outcomes of treatment Change in MF-SAF TSS from baseline after 6 and 12 cycles; symptom response will be determined in participants with baseline MF-SAF TSS ≥ 10. The MF-SAF TSS comprises 7 items measuring MF-related symptoms. Each item is scored on a scale ranging from 0 (absent) to 10 (worst imaginable) and the items are summed for a total score. The Mf-SAF TSS is the summation of all the individual scores (0-70 scale). Symptoms response requires ≥50% reduction in the MPN-SAF TSS and will be evaluable only in patients with a baseline TSS \>= 10.

    Time frame: At 24 weeks and 48 weeks

  3. Change in Patient Global Impression of Change (PGIC)

    Patient Global Impression of Change (PGIC) response after 6 and 12 cycles; PGIC response is defined as "minimally improved" or better The Patient Global Impression of Change (PGIC) will be used to assess self-reported belief about the efficacy of treatment. PGIC is a 7-point scale depicting a patient's rating of overall improvement. Patients rate their change as "very much improved", "much improved", "minimally improved", "no change", "minimally worse", "much worse", or "very much worse. Total scale from 1-7, with higher score indicating poorer health outcomes.

    Time frame: At 24 weeks and 48 weeks

  4. Anemia response

    Anemia response after 6 and 12 cycles; anemia response is determined according to revised 2024 International Working Group-European LeukemiaNet (IWG-ELN) criteria and includes major response rate and minor response rate for transfusion-dependent anemia. Major response: No transfusions for 12 weeks alongside a 12-week average hemoglobin increase of 150g/L Minor response: A 50% or more reduction in transfusions and failure to meet major response thresholds.

    Time frame: At 24 weeks and 48 weeks

  5. Change in hemoglobin level

    Hemoglobin is the protein molecule in red blood cells that carries oxygen from the lungs to the body's tissues and returns carbon dioxide from the tissues back to the lungs.

    Time frame: Continuously across all cycles of treatment, up to 48 weeks

  6. Change in platelet count

    Platelets are part of the blood cells. Platelets are a part of the blood clotting system and help in preventing bleeding.

    Time frame: Continuously across all cycles of treatment, up to 48 weeks

  7. Progression-free survival

    Progression-free survival (PFS) is defined as time from first treatment to disease progression by IWG-ELN criteria

    Time frame: At time of disease progression or at 48 weeks, whichever occurs first

  8. Overall survival

    Overall survival (OS) is defined as time from first treatment to death due to any cause or censored at last follow-up

    Time frame: At time of death or censored at last follow-up, at 48 weeks

  9. Number of participants achieving RBC transfusion independence)

    The number of participants achieving transfusion independence will be divided by the number of participants who were transfusion-dependent at baseline

    Time frame: at 24 weeks and at 48 weeks

  10. Number of participants achieving platelet transfusion independence

    The number of participants achieving transfusion independence will be divided by the number of participants who were transfusion-dependent at baseline

    Time frame: at 24 weeks and at 48 weeks

07

Study locations

1 of 3 sites recruiting
  • The University of Kansas Cancer Center-Westwood
    Westwood, Kansas 66205, United States
    Not yet recruiting
    • Abdulraheem Yacoub · Principal investigator
  • Icahn School of Medicine at Mount Sinai
    New York, New York 10029, United States
    Recruiting
    • John Mascarenhas · Principal investigator
  • Wake Forest Baptist Health Comprehensive Cancer Center
    Winston-Salem, North Carolina 27157, United States
    Not yet recruiting
    • Ruben Mesa · Principal investigator
08

References and documents

Individual participant data

Plan to share: No — The completed dataset is the sole property of the Sponsor-Investigator's institution and should not be exported to third parties, except for authorized representatives of appropriate Health/Regulatory Authorities, without permission from the Sponsor-investigator and their institution.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2026; primary completion for May 2030, 43 months later.

Of 67 non-industry phase 2 interventional studies under Primary Myelofibrosis, half reached primary completion within 76 months of starting (the median), counting those still running; a quarter within 42 and three quarters within 119. This study's planned 43 months is below that.

Counting every sponsor, half of 97 studies reached it within 66 months; a quarter within 32 and three quarters within 111.

Start moved once since we started tracking on Sep 25, 2026: May 2026 → Oct 2026, on Oct 27, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 25, 2026
First posted
Mar 4, 2026
StartEst.
Oct 23, 2026was May 2026
Primary completionEst.
May 24, 2030
CompletionEst.
May 24, 2030
Last update
Oct 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 27, 2026
Sites
3 sites changed recruiting status (2 now not yet recruiting, 1 now recruiting)
Show 3 sites
  • The University of Kansas Cancer Center-Westwood · Westwood, United Statesno status→Not yet recruiting
  • Icahn School of Medicine at Mount Sinai · New York, United Statesno status→Recruiting
  • Wake Forest Baptist Health Comprehensive Cancer Center · Winston-Salem, United Statesno status→Not yet recruiting
Oct 27, 2026
Start date
May 4, 2026→Oct 23, 2026
Oct 27, 2026
Show all 1 update
  1. Oct 27, 2026
    Not yet recruiting→Recruiting
    3 sites changed recruiting status (2 now not yet recruiting, 1 now recruiting)
    Show 3 sites
    • The University of Kansas Cancer Center-Westwood · Westwood, United Statesno status→Not yet recruiting
    • Icahn School of Medicine at Mount Sinai · New York, United Statesno status→Recruiting
    • Wake Forest Baptist Health Comprehensive Cancer Center · Winston-Salem, United Statesno status→Not yet recruiting
    Start date May 4, 2026→Oct 23, 2026
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07447817
Lead sponsor
John Mascarenhas
Responsible party
John Mascarenhas (Professor, Icahn School of Medicine at Mount Sinai) — Sponsor-investigator
First posted
Mar 4, 2026
Start date
Oct 23, 2026 (estimated)
Primary completion
May 24, 2030 (estimated)
Completion
May 24, 2030 (estimated)
Last update
Oct 27, 2026

Study contacts

Gillian Sanchez
Contact
gillian.sanchez@mssm.edu
(917) 581-1774
Shakira Forde
Contact
shakira.forde@mssm.edu
212-824-8334
John Mascarenhas, MD
study chair · Icahn School of Medicine at Mount Sinai
Abdulraheem Yacoub, MD
study chair · University of Kansas School of Medicine
Ruben Mesa, MD, FACP
study chair · Atrium Health Wake Forest Baptist Comprehensive Cancer Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Pacritinib · Selinexor

Start the discussion